Baxter Presents Phase III HyQ Efficacy and Tolerability Data at American … – MarketWatch (press release)

Baxter Presents Phase III HyQ Efficacy and Tolerability Data at American …
MarketWatch (press release)
5, during the American College of Allergy, Asthma and Immunology annual meeting in Boston. "In addition to a reduced rate of serious bacterial infections, the phase III study data suggest potentially useful attributes of HyQ, such as the possibility …

and more »